Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 209

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

THE EFFECT OF PRAVASTATIN ON ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION-A PILOT STUDY1

Katznelson, Steven, Wilkinson, Alan H., Kobashigawa, Jon A., Wang, Xiu-Ming, Chia, David, Ozawa, Mikki, Zhong, Hui-Ping, Hirata, Masaru, Cohen, Arthur H., Terasaki, Paul I., Danovitch, Gabriel M.·1996·Transplantation

Abstract

Hyperlipidemia is an important complication of kidney transplantation affecting up to 74% of recipients. HMG-CoA reductase inhibitors are reported to provide safe and effective treatment for this problem. A recent study suggests that pravastatin, an HMG-CoA reductase inhibitor, also decreases the incidence of both clinically severe acute rejection episodes and natural killer cell cytotoxicity after orthotopic heart transplantation. We have performed a prospective randomized pilot study of the effect of pravastatin on these same parameters after cadaveric kidney transplantation. Graft recipients were randomized to receive pravastatin after transplantation or no pravastatin (24 patients in each group) in addition to routine cyclosporine and prednisone immunosuppression. Lipid levels, acute rejection episodes and serial natural killer cell cytotoxicities were followed for 4 months after the transplant. At the end of the study period, pravastatin had successfully controlled mean total cholesterol levels (202.6 +/- 9.3 vs. 236.5 +/- 11.9 mg/dl, P < 0.02), LDL levels (107.9 +/- 6.6 vs.149.6 +/- 10.7 mg/dl, P < 0.002), and triglyceride levels (118.8 +/- 14.2 vs. 157.2 +/- 13.8 mg/dl, P < 0.05). In addition, the pravastatin-treated group experienced a reduction in the incidence of biopsy-proven acute rejection episodes (25% vs. 58%, P = 0.01), the incidence of multiple rejections episodes (P < 0.05), and the use of both pulse methylprednisolone (P = 0.01) and OKT3 (P = 0.02). Mean natural killer cell cytotoxicity was similarly reduced (11.3 +/- 1.6 vs. 20.0 +/- 2.0% lysis of K562 target cells, P < 0.002). These data suggest that pravastatin exerts an additional immunosuppressive effect in kidney transplant recipients treated with cyclosporine-based immunosuppression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-199605270-00010

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 209

Metadata

Authors
Katznelson, S., Wilkinson, A. H., Kobashigawa, J. A., Wang, X.-M., Chia, D., Ozawa, M., Zhong, H.-P., Hirata, M., Cohen, A. H., Terasaki, P. I., & Danovitch, G. M.
Venue
Transplantation
Published
1996-05
Volume
61
Issue
10
Pages
1469-1474
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2060774684
Cited by
209
References
2
FWCI
11.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: THE EFFECT OF PRAVASTATIN ON ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION-A PILOT STUDY1. https://app.cochat.ai/papers/10.1097/00007890-199605270-00010
The paper
Katznelson, S., Wilkinson, A. H., Kobashigawa, J. A., Wang, X.-M., Chia, D., Ozawa, M., Zhong, H.-P., Hirata, M., Cohen, A. H., Terasaki, P. I., & Danovitch, G. M. (1996). THE EFFECT OF PRAVASTATIN ON ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION-A PILOT STUDY1. Transplantation. https://doi.org/10.1097/00007890-199605270-00010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.